Padsevonil (UCB0942)
| Disease area studied | Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Epilepsy | Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy. | Phase 2 |
EP0069
Completed |
NCT02495844 2014-003330-12 |
LINK LINK |
Van Paesschen W. [abstract 1.289] available on Annual Meeting Abstract Database www.aesnet.org | |
| Epilepsy | An open-label, multicenter, extension study to evaluate the long-term safety, tolerability, and efficacy of UCB0942 when used as adjunctive therapy for partial-onset seizures in adult subjects with highly drug-resistant focal epilepsy Phase 2 | Phase 2 |
EP0073
Terminated |
NCT02625090 2015-001268-20 |
LINK LINK |
||
| Epilepsy | The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy | Phase 2 |
EP0091
Completed |
NCT03373383 2017-003200-48 |
LINK LINK |
Werhahn K.J., et al [abstract 130] 74th Annual Meeting of the American Epilepsy Society (AES), December 04-08, 2020; Online www.aesnet.org | |
| Epilepsy | A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (DUET) | Phase 3 |
EP0092
Completed |
NCT03739840 2018-002303-33 |
LINK LINK |
||
| Epilepsy | Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy | Phase 2/3 |
EP0093
Terminated |
NCT03370120 2017-003241-26 |
LINK LINK |